Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
0.6873
-0.0090 (-1.29%)
At close: Oct 8, 2025, 4:00 PM EDT
0.6900
+0.0027 (0.39%)
After-hours: Oct 8, 2025, 7:17 PM EDT

Company Description

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.

The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.

The company is headquartered in Cambridge, Massachusetts.

Enveric Biosciences, Inc.
Enveric Biosciences logo
CountryUnited States
Founded1994
IndustryBiotechnology
SectorHealthcare
Employees6
CEOJoseph Tucker

Contact Details

Address:
245 First Street, Riverview II
Cambridge, Massachusetts 02142
United States
Websiteenveric.com

Stock Details

Ticker SymbolENVB
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000890821
CUSIP Number29405E208
ISIN NumberUS29405E4061
Employer ID95-4484725
SIC Code2834

Key Executives

NamePosition
Dr. Joseph Edward Tucker Ph.D.Chief Executive Officer and Director
Kevin M. Coveney CPAChief Financial Officer
Dr. Peter J. Facchini Ph.D.Chief Innovation Officer

Latest SEC Filings

DateTypeTitle
Oct 3, 2025SCHEDULE 13GFiling
Oct 3, 2025DNotice of Exempt Offering of Securities
Sep 29, 2025S-3Registration statement under Securities Act of 1933
Sep 24, 2025SCHEDULE 13GFiling
Sep 18, 20258-KCurrent Report
Sep 2, 20258-KCurrent Report
Aug 29, 20258-KCurrent Report
Aug 29, 20258-KCurrent Report
Aug 14, 202510-QQuarterly Report
Aug 14, 20258-KCurrent Report